Dublin, Ireland and North Dakota, USA, October 5th 2021 DS Biopharma Limited, a developer of bioactive lipid-based pharmaceuticals and the NDSU Research Foundation today announced they […]
• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]
Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
Dublin, Ireland, October 18th 2018 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of […]
DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]
